Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.